Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. 2003

Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
Institut National de la Santé et de la Recherche Médicale/Université Pierre et Marie Curie U536, Institut du Fer à Moulin, Paris, France 75005.

Endocannabinoids form a novel class of intercellular messengers, the functions of which include retrograde signaling in the brain and mediation or modulation of several types of synaptic plasticity. Yet, the signaling mechanisms and long-term effects of the stimulation of CB1 cannabinoid receptors (CB1-R) are poorly understood. We show that anandamide, 2-arachidonoyl-glycerol, and Delta9-tetrahydrocannabinol (THC) activated extracellular signal-regulated kinase (ERK) in hippocampal slices. In living mice, THC activated ERK in hippocampal neurons and induced its accumulation in the nuclei of pyramidal cells in CA1 and CA3. Both effects were attributable to stimulation of CB1-R and activation of MAP kinase/ERK kinase (MEK). In hippocampal slices, the stimulation of ERK was independent of phosphatidyl-inositol-3-kinase but was regulated by cAMP. The endocannabinoid-induced stimulation of ERK was lost in Fyn knock-out mice, in slices and in vivo, although it was insensitive to inhibitors of Src-family tyrosine kinases in vitro, suggesting a noncatalytic role of Fyn. Finally, the effects of cannabinoids on ERK activation were dependent on the activity of glutamate NMDA receptors in vivo, but not in hippocampal slices, indicating the existence of several pathways linking CB1-R to the ERK cascade. In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK. The strong potential of cannabinoids for inducing long-term alterations in hippocampal neurons through the activation of the ERK pathway may be important for the physiological control of synaptic plasticity and for the general effects of THC in the context of drug abuse.

UI MeSH Term Description Entries
D008246 Lysophospholipids Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal. Lysophosphatidic Acids,Lysophospholipid,Acids, Lysophosphatidic
D008297 Male Males
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression

Related Publications

Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
January 2005, Neuroscience,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
February 2015, The FEBS journal,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
May 2009, Cell death and differentiation,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
November 2007, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
January 2008, The international journal of biochemistry & cell biology,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
December 2009, The Journal of biological chemistry,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
November 2001, Cancer chemotherapy and pharmacology,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
December 2019, Biochemical and biophysical research communications,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
May 2014, Neuroreport,
Pascal Derkinderen, and Emmanuel Valjent, and Madeleine Toutant, and Jean-Christophe Corvol, and Hervé Enslen, and Catherine Ledent, and James Trzaskos, and Jocelyne Caboche, and Jean-Antoine Girault
January 2003, Molecular pharmacology,
Copied contents to your clipboard!